Month: October 2025
Excerpt from the Press Release: BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Precision in Clinical Trials Summit in San Diego, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read More
Excerpt from the Press Release: SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating…
Read More
Beverly Hills Cancer Center expands patient treatment options in Southern California Excerpt from the Press Release: HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion, an external-beam, theranostic oncology company, today announced that Beverly Hills Cancer Center, a leading private cancer diagnostic and treatment facility, has treated its first patient with the RefleXion® X1 dual-treatment modality radiotherapy platform. This milestone marks…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Clinical Outsourcing Group Bay Area in San Francisco, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read More
Excerpt from the Press Release: Researchers from McMaster University and the Massachusetts Institute of Technology (MIT) have developed a new antibiotic that could change the way doctors treat Crohn’s disease and other forms of inflammatory bowel disease (IBD). The drug enterololin is the first of its kind and is designed to target harmful bacteria in…
Read More
64Cu/177Lu-Tamrada selectively targets tumor associated macrophages (TAMs) arresting tumor growth Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ironfist Therapeutics (“Ironfist”), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor associated macrophages without a targeting ligand, will be presenting positive preclinical proof of concept results in anti-PD-1 resistant triple negative breast (TNB)…
Read More
Assistant Professor Vineet Augustine’s groundbreaking research linking heart-brain connections could revolutionize cardiovascular care Excerpt from the Press Release: Heart disease, which kills millions each year, remains the world’s leading cause of death. While cardiac research has mainly focused on heart attacks as isolated episodes, Assistant Professor Vineet Augustine of the University of California San Diego…
Read More
Key CMC achievements advance EB-003 on the path to first-in-human trials Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced significant progress in the chemistry, manufacturing, and controls (CMC) development of its lead…
Read More
Excerpt from the Press Release: PHILADELPHIA, Oct. 2, 2025 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has treated the first patient with follicular lymphoma (FL) in its CELESTIAL-301 Phase 1 clinical trial of SynKIR™-310. This milestone reflects Verismo’s commitment to addressing the urgent unmet medical…
Read More- « Previous
- 1
- 2
- 3
- Next »